Nyloxin :: Chronic Pain Relief

Blog

Nutra Pharma Letter to Shareholders

Nutra Pharma CEO, Rik J Deitsch, has published a letter to Shareholders outlining the current efforts and the future goals of the Company.

December 18, 2012Coral Springs, Florida — Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the Company’s Chief Executive Officer, Rik J Deitsch, had published a Shareholder Letter on the Company’s website.

“We have been very busy here at Nutra Pharma,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “I wanted to take this opportunity to update our shareholders and the public on the status of the Company and briefly outline our goals and expectations for the coming months,” he concluded.

Click here to read on…

Leave a Reply

Nyloxin is a Registered Trademark of Nutra Pharma Corporation. Copyright © 2009-2011. All Rights Reserved.

Nutra Pharma Corporation